Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 11:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dexamethasone 8 mg Clear all
Withdrawn Phase 2 Interventional

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

NCT02578121
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Pomalidomide, Dexamethasone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 26, 2026, 11:51 PM EDT
Completed Phase 3 Interventional Results available

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

NCT02504489
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Docetaxel + Plinabulin (DP), Docetaxel (D)
Drug
Lead sponsor
BeyondSpring Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
19
States / cities
Chandler, Arizona • Anaheim, California • Whittier, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 26, 2026, 11:51 PM EDT
Completed Phase 1 Interventional

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

NCT02332850
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Carfilzomib, Dexamethasone
Biological · Drug
Lead sponsor
Thomas Martin, MD
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
5
States / cities
San Francisco, California • Denver, Colorado • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 26, 2026, 11:51 PM EDT
Enrolling by invitation Phase 4 Interventional

Comparison of Outcomes of Management of Bowel Obstruction Pilot Study

NCT06817551
View directory record Official record
Conditions
Adhesive Small Bowel Obstruction
Interventions
Dexamethasone, Supportive Care
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 26, 2026, 11:51 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, Lenalidomide, Cilta-cel, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
19
States / cities
San Francisco, California • New Haven, Connecticut • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 26, 2026, 11:51 PM EDT
Active, not recruiting Early Phase 1 Interventional

Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel

NCT04514029
View directory record Official record
Conditions
Lymphoma
Interventions
Simvastatin, Dexamethasone
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 26, 2026, 11:51 PM EDT
Recruiting Phase 3 Interventional

Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

NCT07285239
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years to 79 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 26, 2026, 11:51 PM EDT
Terminated Not applicable Interventional Results available

The Effects of Corticosteroids, Glucose Control, and Depth-of-Anesthesia on Perioperative Inflammation and Morbidity From Major Non-cardiac Surgery (Dexamethasone, Light Anesthesia and Tight Glucose Control (DeLiT Trial))

NCT00995501
View directory record Official record
Conditions
Inflammation, Perioperative Morbidity
Interventions
Dexamethasone Sodium Sulfate, Insulin, anesthesia management, Dexamethasone - placebo, Insulin - Placebo, Anesthesia management -Placebo
Drug · Other
Lead sponsor
d sessler
Other
Eligibility
40 Years to 90 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 26, 2026, 11:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

NCT01677858
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
35
States / cities
Tucson, Arizona • Bakersfield, California • Encinitas, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Sep 26, 2026, 11:51 PM EDT
Terminated Phase 2 Interventional Results available

Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

NCT03044353
View directory record Official record
Conditions
Amyloidosis
Interventions
GSK2315698 (CPHPC), GSK2398852 (anti-SAP mAb)
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 26, 2026, 11:51 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

NCT03314181
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Daratumumab, Venetoclax, Bortezomib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
14
States / cities
Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Sep 26, 2026, 11:51 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT01734928
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Bortezomib, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
92
States / cities
Mobile, Alabama • Tucson, Arizona • Berkeley, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Sep 26, 2026, 11:51 PM EDT
Completed Phase 1Phase 2 Interventional

Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

NCT03236792
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Ixazomib, Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Sep 26, 2026, 11:51 PM EDT
Completed Phase 2 Interventional Results available

Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma

NCT00290511
View directory record Official record
Conditions
Lymphoma
Interventions
Fludarabine, Mitoxantrone, Rituximab, Zevalin, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 26, 2026, 11:51 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

NCT01311687
View directory record Official record
Conditions
Multiple Myeloma
Interventions
pomalidomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 26, 2026, 11:51 PM EDT
Terminated Phase 2 Interventional Results available

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT02419469
View directory record Official record
Conditions
Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoma
Interventions
Cytarabine, Daunorubicin, Vincristine, Prednisone, PEG asparaginase, Ofatumumab, Rituximab, Methotrexate, Cyclophosphamide, Mercaptopurine, Doxorubicin, Dexamethasone acetate, Thioguanine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Sep 26, 2026, 11:51 PM EDT
Active, not recruiting Phase 2 Interventional

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

NCT04270175
View directory record Official record
Conditions
Amyloid, AL Amyloidosis, Refractory AL Amyloidosis
Interventions
Daratumumab SC, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 26, 2026, 11:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

NCT01217957
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Sep 26, 2026, 11:51 PM EDT
Recruiting Phase 4 Interventional

Systemic Oral Glucocorticoids for the Treatment of Acute Osteoarthritis Pain in the Emergency Department

NCT06603662
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis (OA) of the Knee, Osteoarthritis (OA) of the Shoulder, Osteoarthritis (OA) of the Hip
Interventions
Prednisone, Dexamethasone, Placebo
Drug
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 26, 2026, 11:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants

NCT01897389
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Sep 26, 2026, 11:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

NCT00440726
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Bortezomib, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Vincristine, Triple IT Therapy
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 26, 2026, 11:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01355705
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Amrubicin, Lenalidomide, Dexamethasone, Aspirin, Pegfilgrastim
Drug
Lead sponsor
Michaela Liedtke
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Sep 26, 2026, 11:51 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

NCT00302003
View directory record Official record
Conditions
Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma, Childhood Nodular Sclerosis Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma
Interventions
radiation therapy, doxorubicin hydrochloride, vincristine sulfate, prednisone, cyclophosphamide, ifosfamide, vinorelbine tartrate, dexamethasone, etoposide phosphate, cisplatin, cytarabine, filgrastim
Radiation · Drug · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 26, 2026, 11:51 PM EDT
Completed Phase 2 Interventional Results available

Phase II Combination Steroid and Anti-VEGF for Persistent DME

NCT01945866
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
intravitreal ranibizumab 0.3 mg, dexamethasone intravitreal implant, Sham injection
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
56
States / cities
Beverly Hills, California • Huntington Beach, California • Loma Linda, California + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 26, 2026, 11:51 PM EDT